依那西普联合甲氨蝶呤治疗类风湿关节炎的临床疗效及安全性  

Clinical efficacy and safety of etanercept combined with methotrexate in the treatment of rheumatoid arthritis

作　　者：敖亮 刘瑞[2] 李静[1] AO Liang1 , LIU Rui 2, LI Jing1(1. Immunology and Rheumatology Department, Yan＇an University Affiliated Hospital, Yan＇an 716000;2. Neurology Department, Dongguan Branch of Yan＇an University, Yan＇an 716000, China)

机构地区：[1]延安大学附属医院免疫风湿科,陕西延安716000 [2]延安大学东关分院神经内科,陕西延安716000

出　　处：《临床医学研究与实践》2018年第24期51-52,共2页Clinical Research and Practice

摘　　要：目的评价依那西普联合甲氨蝶呤治疗类风湿关节炎(RA)患者的临床疗效和安全性。方法将90例RA患者随机分为试验组和对照组,各45例。试验组给予依那西普联合甲氨蝶呤治疗,对照组给予甲氨蝶呤治疗。比较两组患者治疗前、后的HSS、WOMAC、VAS、SF-36评分及不良反应发生情况。结果治疗后,两组患者的HSS、WOMAC、VAS及SF-36评分均显著改善,且试验组优于对照组(P<0.05)。治疗后,两组患者各不良反应发生率比较,差异均无统计学意义(P>0.05)。结论依那西普联合甲氨蝶呤治疗RA的疗效优于单用甲氨蝶呤,且可以明显提高患者生活质量,不良反应轻微。Objective To evaluate the clinical efficacy and safety of etanercept combined with methotrexate in the treatment of patients with rheumatoid arthritis（RA）. Methods Ninety patients with RA were randomly divided into experimental group and control group, with 45 cases in each group. The experimental group was given etanercept combined with methotrexate, and the control group was given methotrexate. The scores of HSS, WOMAC, VAS and SF-36 before and after treatment and incidences of adverse reactions in the two groups were compared. Results After treatment, the scores of HSS, WOMAC, VAS and SF-36 of the two groups significantly improved, and those of the experimental group were better than the control group（P〈0.05）. After treatment, there were no significant differences in the incidences of adverse reactions between the two groups（P〈0.05）. Conclusion Compared with using methotrexate alone, etanercept combined with methotrexate in the treatment of RA has better efficacy, which can significantly improve the quality of life of patients, with mild adverse reactions.

关 键 词：类风湿关节炎(RA) 依那西普 甲氨蝶呤 

分 类 号：R593.22[医药卫生—内科学]